Y-Intercept (HK)’s Syndax Pharmaceuticals SNDX Stock Holding History

Y-Intercept (HK)’s Portfolio SNDX Stock Details SNDX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$4.65M	Buy	+212,713	New	+$4.42M	0.09%	304
2026 Q1	–	Sell	-155,916	Closed	-$3.28M	–	2018
2025 Q4	$3.28M	Buy	155,916 +55,065	+55%	+$961K	0.07%	387
2025 Q3	$1.55M	Sell	100,851 -176,081	-64%	-$2.3M	0.04%	759
2025 Q2	$2.59M	Buy	+276,932	New	+$3.05M	0.06%	482
2025 Q1	–	Sell	-83,297	Closed	-$1.1M	–	1577
2024 Q4	$1.1M	Buy	83,297 +1,995	+2%	+$34.1K	0.07%	390
2024 Q3	$1.57M	Buy	81,302 +61,916	+319%	+$1.28M	0.1%	278
2024 Q2	$398K	Buy	+19,386	New	+$406K	0.02%	913
2023 Q4	–	Sell	-22,043	Closed	-$320K	–	1612
2023 Q3	$320K	Buy	+22,043	New	+$417K	0.03%	738

Other funds holding SNDX

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

KCM

Kynam Capital Management Princeton, New Jersey $1.81B AUM 192.15% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return

Eversept Partners New York $1.93B AUM 160.8% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

HRCM

Hood River Capital Management Palm Beach Gardens, Florida $13.8B AUM 163.97% 1-Year Est. Return

Y-Intercept (HK)'s SNDX Position: Q2 2026 in Review

Y-Intercept (HK) opened a new position in Syndax Pharmaceuticals (SNDX) in Q2 2026: 212,713 shares worth $4.65M. The stake represents 0.09% of the portfolio and ranks #304 among its holdings. This is a return to the name: Y-Intercept (HK) previously reported a position in SNDX as recently as Q4 2025.

Y-Intercept (HK) first reported a position in SNDX in Q3 2023 and has held it in 8 quarters since. 243 funds tracked by Wall St. Rank hold SNDX as of Q2 2026.

Y-Intercept (HK) held 212,713 shares of Syndax Pharmaceuticals worth $4.65M as of Q2 2026.
Syndax Pharmaceuticals was a new Y-Intercept (HK) position in Q2 2026.
Syndax Pharmaceuticals made up 0.09% of Y-Intercept (HK)'s portfolio in Q2 2026, its #304 holding.
Y-Intercept (HK) first reported a position in Syndax Pharmaceuticals in Q3 2023 and has held it in 8 quarters since.
243 funds tracked by Wall St. Rank held Syndax Pharmaceuticals as of Q2 2026.

Based on Y-Intercept (HK)'s 13F filing for Q2 2026, filed 14 Jul 2026.